Search clinical trials for: Copanlisib Refametinib (BAY86-9766)

Total 28 results

Bayer

Completed

Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer

Neoplasms

United States, Germany, Netherlands
Bayer

Terminated

Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer

Neoplasms

United States
Bayer

Completed

Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

Carcinoma, Hepatocellular

Belgium, France, Switzerland, Germany, United States, Austria, New Zealand, Hungary, Korea, Republic of, Italy, Hong Kong, Thailand, Spain, Taiwan, Japan, Czechia, United Kingdom
Bayer

Completed

Japanese BAY86-9766 Monotherapy Phase I Study

Neoplasms

Japan
Bayer

Completed

Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

Carcinoma, Hepatocellular

Belgium, China, Hong Kong, Switzerland, Japan, France, Spain, Germany, United States, Austria, Czechia, United Kingdom, Korea, Republic of, Thailand, New Zealand, Hungary, Israel, Italy, Taiwan, Singapore, Turkey
Bayer

Completed

Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL

Lymphoma Non-Hodgkin

Japan
Bayer

Completed

Copanlisib Pharmacodynamic Study

Non Hodgkin Lymphoma

Belgium, France, United Kingdom
Bayer

Completed

Copanlisib Mass Balance Study

Healthy Volunteers

Netherlands
Bayer

Active, not recruiting

A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions

Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Taiwan
Bayer

No longer available

Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors

Cancer

Brazil, Hong Kong, Hungary, Malaysia, Poland, Romania, Russian Federation, Taiwan, Ukraine, Ireland, Chile
Bayer

Completed

Study of Copanlisib in Hepatic or Renal Impairment

Hepatic Insufficiency, Renal Insufficiency

Germany, Romania
Bayer

Completed

Copanlisib Chinese PK Study

Lymphoma, Non-Hodgkin

China
Bayer

Completed

BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

Neoplasms

United States
Bayer

Completed

BAY86-9766 Plus Gemcitabine Phase I Study in Asian

Neoplasms

China, Korea, Republic of, Japan
Bayer

Completed

RDEA119 and Sorafenib Combination Dose Escalation Study

Advanced Cancer

United States, Canada
Bayer

Completed

Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (ROCOCO)

Advanced or Metastatic Solid Tumor

United States, Spain, Korea, Republic of, Belgium, Singapore, Germany
Bayer

Terminated

Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Lymphoma, Mantle-Cell

United States
Bayer

Completed

Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse, Large B-Cell, Lymphoma

Belgium, France, Canada, Korea, Republic of, Australia, Germany, United Kingdom, Italy, Denmark, Singapore
Bayer

Completed

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Lymphoma, Non-Hodgkin

Belgium, France, Spain, Hong Kong, Turkey, Russian Federation, Singapore, United States, Canada, Germany, Australia, New Zealand, Finland, Austria, United Kingdom, Bulgaria, Hungary, Italy, Israel, Korea, Republic of, Poland, Port... and more
Bayer

Completed

Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics

Healthy Volunteers

United States
Cancer Trials Ireland

Completed

Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) (Panther)

HER2 Positive Breast Cancer

Ireland
Bayer

Completed

Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer. (BASIL)

Carcinoma, Hepatocellular

Hong Kong, Taiwan, Korea, Republic of, Singapore
Bayer

Completed

Combination With Gemcitabine in Advanced Pancreatic Cancer (BAGPAC)

Pancreatic Neoplasms

United Kingdom, Germany, United States, Czechia, Belgium, Norway, Poland, Italy, France
Bayer

Active, not recruiting

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-3)

Lymphoma,Non-Hodgkin

China, Hong Kong, Spain, Taiwan, Turkey, Japan, Russian Federation, Singapore, France, Austria, Bulgaria, Korea, Republic of, Malaysia, Thailand, United States, Germany, Hungary, Italy, Philippines, Romania, Poland, Portugal, Mexico, ... and more
Bayer

Completed

Effect of Ketoconazole on the Pharmacokinetics of Refametinib

Drug Interactions

United States
Bayer

Completed

Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

Neoplasms

United States
Bayer

Completed

COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients

Medical Oncology

Canada, United States
Bayer

Terminated

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-4)

Lymphoma, Non-Hodgkin

United States, Hungary, China, Belgium, Korea, Republic of, France, Australia, Russian Federation, Taiwan, Denmark, Japan, United Kingdom, Spain, South Africa, Turkey, Romania, Singapore, Israel, Ireland, Canada, Poland, Greece, Cze... and more

Search clinical trials for: Copanlisib Refametinib (BAY86-9766)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations